Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Kingsoft Cloud Holdings Limited — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Kingsoft Cloud Holdings Limited trades at $11.72 (market cap $3.53B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 8.4× Kingsoft Cloud Holdings Limited's market cap, and Kingsoft Cloud Holdings Limited is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | KC | |
|---|---|---|
Market Cap | $29.60B | $3.53B |
Sector | Health | Technology |
52-Week High | $491.22 | $18.21 |
52-Week Low | $205.48 | $8.58 |
Enterprise Value | $27.56B | $3.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Kingsoft Cloud (KC) trades at $11.75, down 1.76% today, with a bullish technical signal supported by moving averages. The company shows strong revenue growth trends (37% YoY in Q1 2026) and has beaten EPS estimates for three consecutive quarters, though it remains unprofitable with a -9.39% net margin. Recent news highlights AI-driven growth momentum, with AI cloud billing now exceeding half of public cloud revenue.
The outlook is cautiously optimistic with 70% analyst buy ratings, but profitability challenges and significant capital expenditures pose risks. The stock's valuation appears reasonable with P/S of 2.22, though negative ROE and ROA indicate operational inefficiencies that need addressing for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
